JPRN-jRCTs031180134已完成3 期
Clinical trial for pre-exposure prophylaxis for HIV infection toward Tokyo Olympic
Mizushima Daisuke0 个研究点目标入组 124 人开始时间: 2019年2月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 124
研究概览
简要总结
The present study showed that the prophylactic effect against HIV infection and the retention and adherence rates of PrEP were high, although PrEP initiation increased the incidence of STI among Japanese MSM. The use of PrEP in Japan is feasible, and therefore, the implementation of PrEP is highly recommended, combined with safer sex promotion.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •1. Non HIV-infected MSM who have anal sexual intercouse.
- •2. Aged 20 years or over
- •3. At high risk for acquiring HIV infection as below
- •Had STI within one year
- •Had anal sexual intercouse without condome use within 6 months
- •Have sex partners with HIV infection
- •Had use of stimulants within 6 months
- •4. Live in Japan and understand Japanese
- •5. Participate in a MSM cohort study Sexual Health Clinic and continue to
- •attend the cohort for one year and understand importance and significance of
- •HIV prevention by PrEP.
- •6. Willing and able to provide informed consent
排除标准
- •1. Suspected acute HIV infected
- •2. Having severe hepatic disorder or renal dysfunction(eGFR<60ml/min/1.73m2)
- •3. Concurrently taking a nephrotoxic agent (e.g.high-dose non-stroidal antiinflammatory drugs/NSAIDs)
- •4. Allergic to TDF and/or FTC
- •5. Concurrently taking prescribed products containing TDF or FTC
- •6. Possiblity to be unable to continue taking truvada during the study period
- •7. Considered to be inadequate for PrEP due to other factors
研究者
相似试验
已完成
不适用
PrEP and Alcohol - Enhancing HIV Pre-Exposure Prophylaxis (PrEP)Hazardous Alcohol UseNCT05097430Centre for Addiction and Mental Health122
已完成
2 期
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk WomenHIV InfectionNCT01505114National Institute of Allergy and Infectious Diseases (NIAID)594
已完成
1 期
First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy VolunteersHIVNCT01719627Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia10
招募中
3 期
Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTHIV InfectionsNCT06250504Africa Health Research Institute2,052
已完成
2 期
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)HIV InfectionsNCT01327651HIV Prevention Trials Network622